Walvax Biotechnology Co., Ltd.
300142
Pozycja w akcjach
#4861
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical... Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
Cena akcji
$1.87
Kapitalizacja rynkowa
$2.98B
Zmiana (1 dzień)
-3.71%
Zmiana (1 rok)
14.73%
Kraj
CN
Handel Walvax Biotechnology Co., Ltd. (300142)
Kategoria
Healthcare
Marża operacyjna dla Walvax Biotechnology Co., Ltd. (300142)
Marża operacyjna na dzień October 2026 TTM: 6.19%
Według najnowszych raportów finansowych i ceny akcji Walvax Biotechnology Co., Ltd., bieżąca marża operacyjna (TTM) wynosi 6.19%. Na koniec 2024 wynosiła 3.43%.
Historia marży operacyjnej dla Walvax Biotechnology Co., Ltd. od 2007 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 6.19% | 113.45% |
| 2025 | 2.90% | -15.45% |
| 2024 | 3.43% | -77.01% |
| 2023 | 14.92% | -30.99% |
| 2022 | 21.62% | 5.41% |
| 2021 | 20.51% | -56.20% |
| 2020 | 46.83% | 125.47% |
| 2019 | 20.77% | 37.82% |
| 2018 | 15.07% | -169.87% |
| 2017 | -21.57% | -20.20% |
| 2016 | -27.03% | -69.72% |
| 2015 | -89.28% | -601.01% |
| 2014 | 17.82% | 2,870.00% |
| 2013 | 0.60% | -98.55% |
| 2012 | 41.43% | -17.52% |
| 2011 | 50.23% | 1.89% |
| 2010 | 49.30% | 32.21% |
| 2009 | 37.29% | 95.24% |
| 2008 | 19.10% | 338.07% |
| 2007 | 4.36% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 19.41% | -96.86% |
DE
|
|
| 19.68% | -96.82% |
DE
|
|
| 10.52% | -98.30% |
JP
|
|
| 17.08% | -97.24% |
CH
|
|
| 22.93% | -96.30% |
IN
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.